Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Coombes

Showing results (331-340 of 334) with videos related to

Pageof 34
Sort By:
You have reached the last page of results.This site can display upto 334 results.
Cancer Discovery|June 13, 2015
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilitiesFerdinandos Skoulidis, Lauren A Byers, Lixia Diao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 24, 2012
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistanceLauren Averett Byers, Lixia Diao, Jing Wang, et al.
Cell|April 24, 2018
Chemistry-First Approach for Nomination of Personalized Treatment in Lung CancerElizabeth A McMillan, Myung-Jeom Ryu, Caroline H Diep, et al.
Physical Review Letters|April 6, 2001
Measurement of CP-violating asymmetries in B0 decays to CP eigenstatesB Aubert, D Boutigny, I De Bonis, et al.
Pageof 34

Showing results (331-340 of 334) with videos related to

Sort By:
Pageof 34
You have reached the last page of results.This site can display upto 334 results.
Cancer Discovery|June 13, 2015
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilitiesFerdinandos Skoulidis, Lauren A Byers, Lixia Diao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 24, 2012
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistanceLauren Averett Byers, Lixia Diao, Jing Wang, et al.
Cell|April 24, 2018
Chemistry-First Approach for Nomination of Personalized Treatment in Lung CancerElizabeth A McMillan, Myung-Jeom Ryu, Caroline H Diep, et al.
Physical Review Letters|April 6, 2001
Measurement of CP-violating asymmetries in B0 decays to CP eigenstatesB Aubert, D Boutigny, I De Bonis, et al.
Pageof 34